Complement contributes to antibody-mediated protection against repeated SHIV challenge.

ABSTRACT: The first clinical efficacy trials of a broadly neutralizing antibody (bNAb) resulted in less benefit than expected and suggested that improvements are needed to prevent HIV infection. While considerable effort has focused on optimizing neutralization breadth and potency, it remains unclear whether augmenting the effector functions elicited by broadly neutralizing antibodies (bNAbs) may also improve their clinical potential. Among these effector functions, complement-mediated activities, which can culminate in the lysis of virions or infected cells, have been the least well studied. Here, functionally modified variants of the second-generation bNAb 10-1074 with ablated and enhanced complement activation profiles were used to examine the role of complement-associated effector functions. Whe

SUBMITTER: Goldberg BS 

PROVIDER: S-EPMC10193994 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature